CenTrial Logo

After Giving Up, a Clinical Trial Saved Laura's Life


At the age of 28, Laura Dixon was diagnosed with colon cancer and 17 years later, she received surgical treatment for pancreatic cancer. A year after that, her condition worsened again and she was diagnosed with ovarian and endometrial cancer while undergoing a hysterectomy. 

The cause for this series of cancers was hereditary non-polyposis colorectal cancer, known as HNPCC or Lynch syndrome. This genetic syndrome puts patients at high risk of developing several cancers, including the ones Laura experienced. 

A new life after successful clinical trial

Laura was fighting with more than two cancers at a time, and her ovarian cancer treatment had to be cut short due to side-effects from the medication she was taking. To make matters worse, her pancreatic cancer had spread to her liver.

Eventually, doctors ran out of options, and the toxic effects from her treatments, while making her miserable, only promised to prolong her life a few short weeks. According to Laura, it wasn't the first time she'd heard she had a very limited time to live. But this time Laura decided to quit the treatment and leave everything to destiny. 

Laura's father on the other hand wasn't ready to quit. He started requesting second opinions from several high-end oncologists across the country. 

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Laura Enrolls in a Clinical Trial

Fortunately, his efforts lead to Laura volunteering at Richard J. Solove Research Institute and OSUCCC-James Cancer Hospital for an immunotherapy clinical trial based on testing pembrolizumab, an intravenous drug.

Pembrolizumab had proved to be effective in cases of "microsatellite instability" -- cells that have a high number of mutations when replicating.  Laura's cells lost their ability to repair tiny DNA errors which resulted in cancers with unchecked cellular growth.

Pembrolizumab has proven to be instrumental in enhancing the survival rate of patients with Lynch syndrome, and thankfully this proved to be the case with Laura.

Laura's Experience

After 17 treatments, Laura's liver cancer was gone, and Lynch syndrome has become diagnosable via genetic testing, raising hopes for other patients.

Laura now exercises 90 minutes every day, attends a full-time job at a Columbus area insurance company, and recently went horseback riding with her father. 

Laura is thankful for her new life and pushes herself to do things outside of her comfort zone – just because she can!

Share this article with a friend:

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.